Triptorelin

Limits on what this shows

• Key negative/null: The hepatic study explicitly reports the oxidative signal was lower at day 360 than at day 270, "due to an increase in the activity of antioxidant enzymes and a decrease in the production of reactive oxygen species" - a partly self-limiting course, not a monotonic worsening.
• At-risk subgroups: None established in humans; both findings are animal-only.
• Counter-evidence: The neural study is a genuine reverse-direction (protective) finding under a specific chemotherapy co-exposure, and argues against treating triptorelin as a uniform mitochondrial toxicant.

Regulatory status

Not addressed in the FDA label; both supporting studies are preclinical.

Population evidence

Study 1 (burden signal): 30 male Wistar rats (10 control, 20 treated with triptorelin 0.3 mg/kg subcutaneously) followed to day 360, with assessments at days 270 and 360. Study 2 (protective signal): 40 male Sprague-Dawley rats (10 per group), triptorelin (Decapeptyl) 0.05 mg/kg/day subcutaneously for 4 weeks, co-administered with cyclophosphamide; anti-p53 staining fell and anti-Bcl-2 staining rose in hippocampus and cerebral cortex versus chemotherapy-only controls.

Mechanism

Named: testosterone normally restrains macrophage and mitochondrial reactive-oxygen output; its removal, the intended pharmacodynamic effect of triptorelin, is proposed to permit increased hepatic mitochondrial-associated oxidative burden over time. The neural finding is attributed to a distinct anti-apoptotic (p53/Bcl-2) signaling effect, not to a shared mitochondrial-ROS mechanism.

Counter-evidence held on record

Animal, mechanistic evidence only; no human mitochondrial biomarker (muscle biopsy respiratory-chain activity, blood lactate/pyruvate ratio, etc.) has been measured in triptorelin-treated patients. Do not treat this as grounds for CoQ10, carnitine, riboflavin, or other "mitochondrial support" supplementation; no dose is recommended for a yellow-tier finding.

Limits on what this shows

• Key negative/null: Adaptive antioxidant-enzyme upregulation partially normalized the biochemical picture by day 360; no irreversible pattern was demonstrated within the study window.
• At-risk subgroups: None established in humans.
• Counter-evidence: No study directly contradicts this finding, but it has not been replicated in humans. A distinct, milder clinical correlate exists: LiverTox reports serum transaminase elevations in 2-5% of triptorelin patients, "rarely above three times the upper limit of normal," usually resolving without dose change.

Regulatory status

None; preclinical only.

Population evidence

Same study as the Mitochondrial burden entry above (cross-referenced in the Overlap map): 30 male Wistar rats, triptorelin 0.3 mg/kg subcutaneously, assessed at days 270 and 360. Hepatocytes showed "karyopyknosis of the nuclei, oxyphilia of the cytoplasm with the appearance of a significant number of vacuoles" and microcirculatory stasis.

Mechanism

Named: loss of testosterone's restraining effect on hepatic oxidative/inflammatory tone during prolonged central LH suppression.

Counter-evidence held on record

Preclinical, single-model evidence; no human oxidative-stress biomarker study (e.g., plasma MDA, F2-isoprostanes, glutathione) in triptorelin-treated patients was located. Do not infer that antioxidant supplementation (vitamin E, vitamin C, N-acetylcysteine, or similar) is indicated on the basis of this finding; none is recommended here.

Limits on what this shows

• Key negative/null: The source study is about testosterone repletion in men already made hypogonadal by a GnRH agonist, not about the hypogonadal state alone; the deprivation-side effect is inferred by reversal, not directly demonstrated in an androgen-deprivation-only arm.
• At-risk subgroups: None established specifically for triptorelin; by analogy, longer-duration androgen-deprivation therapy in men and profound estrogen/androgen suppression in central precocious puberty or endometriosis use.
• Counter-evidence: None directly contradicting, but the inference is one mechanistic and one drug step removed from triptorelin (different GnRH agonist, opposite hormonal direction).

Regulatory status

Not addressed in the Trelstar label, which reports decreased hemoglobin/RBC (see the Oxygen delivery/utilization entry) without an iron-panel explanation.

Population evidence

Tier C for triptorelin. Source cohort: 109 men (53 aged 19-35; 56 aged 59-75) whose endogenous testosterone was suppressed with a GnRH agonist (leuprolide, not triptorelin), then randomized to graded weekly testosterone enanthate doses (25-600 mg) for 20 weeks. Higher testosterone dosing suppressed serum hepcidin within 1 week and predicted a rise in hematocrit, more markedly in older men. Triptorelin itself was not in this cohort; the inference for triptorelin runs in the opposite direction (androgen withdrawal, not repletion).

Mechanism

Named: the testosterone-hepcidin axis. Removing androgen (triptorelin's intended effect) would be expected to raise hepcidin and restrict iron availability for erythropoiesis - the inverse of what this study showed for rising testosterone.

Counter-evidence held on record

This is class-level mechanistic reasoning by reversal, not direct triptorelin evidence. The anemia pattern it would predict is a functional, hepcidin-driven iron restriction, not a true iron-deficiency state. Do not supplement iron in a triptorelin-treated patient with anemia without first confirming true iron deficiency (low ferritin, low transferrin saturation) by standard labs; empiric iron supplementation in a functional/hepcidin-mediated anemia is unlikely to help and adds unnecessary iron burden.

Limits on what this shows

• Key negative/null: The leuprolide study is itself a null finding for a direct treatment effect on brain copper concentration ("did not significantly alter"), the most direct and informative negative result located for any GnRH agonist and copper. A direct Crossref query for "triptorelin trace element zinc ceruloplasmin" returned ten results, none of them about triptorelin.
• At-risk subgroups: None established for triptorelin, or for either class member; the leuprolide finding is a mouse brain-tissue result and the goserelin finding is in vitro cell-culture chemistry, not a patient population.
• Counter-evidence: The leuprolide study's own null result on direct treatment effect weighs against, not for, a copper-status change from GnRH-agonist treatment generally. Neither class-member finding was generated in triptorelin-treated animals or patients, and the goserelin coordination chemistry is cell-free/cell-culture reactivity, not a demonstrated human copper-status effect even for goserelin itself.

Regulatory status

Not addressed in the Trelstar label.

Population evidence

Tier C for triptorelin, built from two class members. (1) "Estropause, Sex Hormones and Metal Homeostasis in the Mouse Brain" (Liu, Bowen, Wilson, Atwood, Frontiers in Neurology, 2022): 7.5-month-old intact, sham-ovariectomized, and ovariectomized C57B6SJL mice treated with leuprolide acetate 1.5 mg/kg biweekly then monthly for 9 months. This review independently opened the full abstract. Brain copper (along with Fe, Zn, Mn, Co, Ni, Al, Li) showed "a tendency for a decrease" following ovariectomy that was reversed with leuprolide treatment, but the paper states plainly that "modulation of plasma sex steroid and gonadotropin levels did not significantly alter the concentrations of brain metals tested," including copper - a null result for a direct leuprolide effect. Brain copper was, however, the one metal that correlated significantly with plasma LH (r=-0.37, n=30, p<0.05) and FSH (r=-0.42, n=29, p<0.01) across the whole cohort. (2) "Impact of the Cu(II) ions on the chemical and biological properties of goserelin: coordination pattern, DNA degradation, oxidative reactivity and in vitro cytotoxicity" (Walencik et al., Journal of Inorganic Biochemistry, 2017): this review independently confirmed the paper's existence, full title, authors, journal, volume, and DOI across the Crossref API, the OpenAlex API, and the authors' own Jagiellonian University institutional repository listing. The title itself establishes that goserelin's peptide structure coordinates Cu(II) ions with resulting DNA-degrading and oxidative reactivity in vitro; the paper's full abstract and quantitative results could not be opened this session (no abstract field via Crossref or OpenAlex, no accessible full text or bitstream at the repository landing page, and a 404 on the ScienceDirect abstract page), so the specific coordinating residue and effect magnitude are not asserted here.

Mechanism

Plausible, not confirmed, for triptorelin: goserelin and triptorelin share the identical pGlu-His-Trp-Ser-Tyr N-terminal sequence, including the histidine-2 residue that is the classic copper-coordination site in peptides, so a structurally similar Cu(II) interaction is plausible for triptorelin, but this has not been tested and the exact goserelin coordination site could not be confirmed from an openly accessible source this session. Separately, the leuprolide brain study's LH/FSH-copper correlation suggests gonadotropin suppression, the mechanism triptorelin shares with every GnRH agonist, may relate to brain copper handling, though the direct treatment effect was not statistically significant even for leuprolide.

Counter-evidence held on record

This is class-level evidence from two other GnRH agonists, not a triptorelin-specific copper finding. One of the two studies is itself a null result for direct treatment effect, and the other's mechanistic detail could not be independently opened this session. Do not infer that copper supplementation or restriction is indicated in a triptorelin-treated patient on the basis of this entry; no dose is recommended for a yellow-tier finding.

Limits on what this shows

• Why no grade: Both conditions for ungraded were checked and genuinely met: a WebSearch for "triptorelin gut microbiome" returned no drug-specific or class-relevant results, and a follow-up Crossref API query for "triptorelin gut microbiota microbiome" returned five results, none of which mentioned triptorelin or any GnRH agonist. No circulating consumer claim linking triptorelin to gut microbiome changes was identified either. This reflects a genuine literature gap encountered through working channels, not a tooling block.

Limits on what this shows

• Key negative/null: The label does not quantify the average hemoglobin drop or report grade 3/4 anemia, and characterizes the lab changes as "mild to moderate." A separate triptorelin-vs-leuprolide comparison in 62 children with central precocious puberty did not evaluate any hematologic lab parameters at all (an unmeasured gap, not a tested negative).
• At-risk subgroups: Older men treated for prostate cancer (the population studied for these formulations); duration-dependent, most clearly documented from the day-253 visit onward. Not established in the pediatric central-precocious-puberty or endometriosis populations.
• Counter-evidence: These trials were not designed to separate triptorelin's contribution from prostate cancer itself, age-related marrow changes, or comorbidity; no placebo/no-treatment comparator arm is available for this bound.

Regulatory status

Reported in the FDA-approved Trelstar label's clinical laboratory-findings tables for all three approved depot strengths.

Population evidence

3.75 mg formulation trial (n=140): anemia reported in 2 patients (1.4%). 11.25 mg formulation trial (n=174): "decreased hemoglobin and RBC count and increased glucose, BUN, SGOT, SGPT, and alkaline phosphatase at the Day 253 visit." 22.5 mg formulation trial (n=120): "decreased hemoglobin and increased glucose and hepatic transaminases were detected during the study. The majority of the changes were mild to moderate."

Mechanism

Named as a candidate, not confirmed for this drug: functional, hepcidin-mediated iron-restricted erythropoiesis secondary to androgen withdrawal (see the Iron entry below and the Overlap map - this is inference, not a second independent data source).

Counter-evidence held on record

This is anemia as a hematologic outcome of profound androgen suppression, not evidence of a classical iron, B12, or folate deficiency - no iron panel (ferritin, transferrin saturation) was reported in these trials. Do not start iron, B12, or folate supplementation on the basis of this finding alone. Any anemia in a triptorelin-treated patient should get a standard hematologic workup before assuming a deficiency etiology; a functional, hepcidin-driven pattern would not respond to iron supplementation and unnecessary iron loading carries its own risk.

Limits on what this shows

• Why no grade: Both conditions for ungraded were checked and genuinely met: a Crossref API query for "triptorelin ATP energy metabolism" returned five results, all about ATP/cellular energy metabolism in general, none mentioning triptorelin. No circulating consumer "low energy" or ATP-specific claim tied to triptorelin was identified. This is separate from, and should not be merged with, the mitochondrial-burden and oxidative-stress entries above, which concern structural/redox mitochondrial signals rather than measured ATP output.